Ley 29459 Structure and Chapters: Peru Medical Device Law Explained

Regulatory information verified as of October 29, 2026.

1. Key takeaways

Ley N° 29459 organizes the full life cycle of pharmaceutical products, medical devices and sanitary products through chapters rather than a dedicated device chapter, and two of them form the main compliance lines for devices: Capítulo IV (sanitary registration) and Capítulo XII (control and sanitary vigilance). The articles companies trip over most often are Art. 8 and Art. 11: the former was amended by Ley N° 31091 on 2020-12-17, and the latter establishes the duty of timely re-registration (Reinscripción). The law was published on 2009-11-26, and what it replaced was Chapter III of Ley N° 26842 (the General Health Law, published 1987-07-15), not the entire General Health Law. Reading registration and vigilance as two unrelated modules is the most typical structural misjudgment seen in Peru projects, and it leads directly to gaps in post-market obligations and to certificates that lapse without a planned renewal.

2. Legal basis

Regulatory information verified as of October 29, 2026.

3. Expert insights

Insight 1: The replacement is chapter-level, not whole-law level.

Ley N° 29459 replaced Chapter III of Ley N° 26842, which means the rest of the General Health Law remains in force; only the specific rules for pharmaceutical products, medical devices and sanitary products moved to the new law. The mechanical consequence is that general obligations in the health field, such as the basic rules governing health facilities and health activities, may still require going back to the General Health Law for a legal basis, while product access and vigilance questions fall under the new law. If a company records in its compliance matrix the premise that Ley N° 26842 has been repealed in its entirety, it will leave gaps in its quality system documentation and its chain of authorizations.

Insight 2: Capítulo IV and Capítulo XII operate in sequence, not in parallel.

A sanitary registration is not the end point of compliance; it is the trigger for vigilance obligations. Once a product holds a sanitary registration, the registration holder immediately assumes reporting duties under pharmacovigilance and technovigilance (Farmacovigilancia y Tecnovigilancia), with the rhythm specified by R.M. N° 539-2016/MINSA, published on 2016-07-27: serious adverse events must be reported within 24 hours, and moderate and mild suspected adverse events within 20 calendar days. This structure, in which one chapter issues the certificate and the next chapter closes the loop, means the vigilance system must be built in parallel with the registration dossier, not retrofitted after the certificate is granted. Companies that postpone vigilance readiness until after approval routinely fail their first inspection.

Insight 3: Art. 8 is a sensitive article repeatedly touched by policy legislation.

Art. 8 was amended by Ley N° 31091, published on 2020-12-17, which shows that the article sits at the entrance to access policy: any legislative action that expands or adjusts market access tends to land there first. Adjacent to it is the duty of timely re-registration established by Art. 11, which together with the 5-year validity period in D.S. N° 016-2011-SA and the filing window of 1 year before expiry under Art. 7 forms a single timeline: validity runs 5 years from the granting date, and the window opens 1 year before expiry. A company that starts re-registration only a few months before expiry will face both a certificate gap and difficulty proving continuity of the registration.

4. Practical recommendations

1. Build a chapter-duty-owner mapping table: assign the access obligations of Capítulo IV and the vigilance obligations of Capítulo XII to specific roles, so that vigilance does not become ownerless once the certificate is obtained.
2. Build a re-registration calendar anchored to the granting date: validity is 5 years and the filing window opens 1 year early; reserve time on the calendar for correcting observations (Observaciones).
3. Track subsequent changes to Art. 8: the article has already been amended once by Ley N° 31091 and is policy-sensitive; base project decisions on the current official text.
4. Move vigilance forward: identify the in-country vigilance owner and reporting channels at the dossier stage, so the 24-hour and 20-calendar-day deadline lines are actually executable.
5. Cite the old law with its hierarchy noted: general rules in the health field may still trace back to Ley N° 26842, but its Chapter III must never be cited as current law.

5. Verification checklist

□ Confirmed that the current framework law is Ley N° 29459 (published 2009-11-26)

□ Confirmed that the scope of replacement was Chapter III of Ley N° 26842, not the entire General Health Law

□ Confirmed that Art. 8 was amended by Ley N° 31091 (2020-12-17) and that the current text controls

□ Confirmed that sanitary registration validity is 5 years and the re-registration window opens 1 year before expiry

□ Confirmed vigilance deadlines: serious events 24 hours; moderate and mild events 20 calendar days

□ Confirmed that the in-country vigilance owner and reporting channels were designated at the dossier stage

Regulatory information verified as of October 29, 2026.

GRZAN Regulatory Team

GRZAN provides medical device registration support in Peru for manufacturers, importers and authorized representatives. For inquiries, contact info@grzanglobal.com.